These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 24198301)

  • 1. Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012.
    Turner LW; Nartey D; Stafford RS; Singh S; Alexander GC
    Diabetes Care; 2014 Apr; 37(4):985-92. PubMed ID: 24198301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ambulatory noninsulin treatment of type 2 diabetes mellitus in the United States, 2015 to 2019.
    Heyward J; Christopher J; Sarkar S; Shin JI; Kalyani RR; Alexander GC
    Diabetes Obes Metab; 2021 Aug; 23(8):1843-1850. PubMed ID: 33881795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in Insulin Types and Devices Used by Adults With Type 2 Diabetes in the United States, 2016 to 2020.
    Sarkar S; Heyward J; Alexander GC; Kalyani RR
    JAMA Netw Open; 2021 Oct; 4(10):e2128782. PubMed ID: 34636912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in National Diabetes Treatment Patterns and Trends between Older and Younger Adults.
    Pilla SJ; Segal JB; Alexander GC; Boyd CM; Maruthur NM
    J Am Geriatr Soc; 2019 May; 67(5):1066-1073. PubMed ID: 30703251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sulfonylurea Prescribing Patterns After the Introduction of DPP-4 Inhibitors and GLP-1 Receptor Agonists.
    Payk SL; Drew RH; Smith JD; Jiroutek MR; Holland MA
    Clin Ther; 2015 Jul; 37(7):1477-1482.e1. PubMed ID: 26024569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in glitazone use among office-based physicians in the U.S., 2003-2009.
    Cohen A; Rabbani A; Shah N; Alexander GC
    Diabetes Care; 2010 Apr; 33(4):823-5. PubMed ID: 20103549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease.
    Chen JJ; Wu CY; Jenq CC; Lee TH; Tsai CY; Tu HT; Huang YT; Yen CL; Yen TH; Chen YC; Tian YC; Yang CW; Yang HY
    JAMA Netw Open; 2022 Mar; 5(3):e221169. PubMed ID: 35254430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. National trends in treatment of type 2 diabetes mellitus, 1994-2007.
    Alexander GC; Sehgal NL; Moloney RM; Stafford RS
    Arch Intern Med; 2008 Oct; 168(19):2088-94. PubMed ID: 18955637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019.
    McCoy RG; Van Houten HK; Deng Y; Mandic PK; Ross JS; Montori VM; Shah ND
    JAMA Netw Open; 2021 Feb; 4(2):e2035792. PubMed ID: 33523188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Second-Generation Diabetes Medication Initiation Among Medicare Enrollees From 2007 to 2015.
    Gilstrap LG; Blair RA; Huskamp HA; Zelevinsky K; Normand SL
    JAMA Netw Open; 2020 May; 3(5):e205411. PubMed ID: 32442290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
    Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myocardial infarction in type 2 diabetes using sodium-glucose co-transporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor agonists: proportional hazards analysis by deep neural network based machine learning.
    Yamada T; Iwasaki K; Maedera S; Ito K; Takeshima T; Noma H; Shojima N
    Curr Med Res Opin; 2020 Mar; 36(3):403-409. PubMed ID: 31855074
    [No Abstract]   [Full Text] [Related]  

  • 14. Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis.
    Zheng SL; Roddick AJ; Aghar-Jaffar R; Shun-Shin MJ; Francis D; Oliver N; Meeran K
    JAMA; 2018 Apr; 319(15):1580-1591. PubMed ID: 29677303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of antidiabetic drugs in the U.S., 2003-2012.
    Hampp C; Borders-Hemphill V; Moeny DG; Wysowski DK
    Diabetes Care; 2014; 37(5):1367-74. PubMed ID: 24623020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycaemia in patients with type 2 diabetes: a cohort study using the UK Clinical Practice Research Datalink.
    Gamble JM; Chibrikov E; Midodzi WK; Twells LK; Majumdar SR
    BMJ Open; 2018 Oct; 8(10):e023830. PubMed ID: 30297350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. National Trends in Use of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020.
    Adhikari R; Jha K; Dardari Z; Heyward J; Blumenthal RS; Eckel RH; Alexander GC; Blaha MJ
    J Am Heart Assoc; 2022 May; 11(9):e023811. PubMed ID: 35475341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Asthma Exacerbations in Patients with Type 2 Diabetes and Asthma on Glucagon-like Peptide-1 Receptor Agonists.
    Foer D; Beeler PE; Cui J; Karlson EW; Bates DW; Cahill KN
    Am J Respir Crit Care Med; 2021 Apr; 203(7):831-840. PubMed ID: 33052715
    [No Abstract]   [Full Text] [Related]  

  • 19. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus--a retrospective nationwide study.
    Mogensen UM; Andersson C; Fosbøl EL; Schramm TK; Vaag A; Scheller NM; Torp-Pedersen C; Gislason G; Køber L
    Diabetes Obes Metab; 2014 Oct; 16(10):1001-8. PubMed ID: 24827939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. National ambulatory care non-insulin antidiabetic medication prescribing trends in the United States from 2009 to 2015.
    Kitten AK; Kamath M; Ryan L; Reveles KR
    PLoS One; 2019; 14(8):e0221174. PubMed ID: 31412090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.